natgillin/translations-raw huggingface dataset:
An increase to a dose greater than the recommended starting dose is advised only after
Zvišanje odmerka na ve kot priporo eni za etni odmerek je priporo ljivo le po ustrezni ponovni klini ni oceni, odmerki naj se v splošnem višajo po preteku vsaj 24- urnega asovnega intervala.
ZYPREXA VELOTAB Orodispersible Tablet should be placed in the mouth, where it will rapidly disperse in saliva, so it can be easily swallowed.
ZYPREXA VELOTAB orodisperzibilno tableto naj se položi v usta, kjer se hitro dispergira v slini, tako da jo je mogo e brez težav pogoltniti.
Alternatively, it may be dispersed in a full glass of water or other suitable beverage (orange juice, apple juice, milk or coffee) immediately before administration.
Drug na in uporabe je, da tableto dispergiramo v polnem kozarcu vode ali druge ustrezne pija e (pomaran ni sok, jabol ni sok, mleko ali kava) neposredno pred zaužitjem.
Children and adolescents Olanzapine is not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy.
Otroci in mladostniki Zaradi pomanjkanja podatkov glede varnosti in u inkovitosti, olanzapina ne priporo amo za uporabo pri otrocih in mladostnikih mlajših od 18 let.
A greater magnitude of weight gain, lipid and prolactin alterations has been reported in short term studies of adolescent patients than in studies of adult patients (see sections 4.4, 4.8, 5.1 and 5.2).
V kratkoro nih študijah pri bolnikih mladostnikih so poro ali o ve jem obsegu pove anja telesne mase, spremembah lipidov in prolaktina, kot v študijah pri odraslih bolnikih (glejte poglavja 4. 4, 4. 8, 5. 1 in 5. 2).
Elderly A lower starting dose (5 mg/ day) is not routinely indicated but should be considered for those 65 and over when clinical factors warrant (see section 4.4).
Starejši Nižji za etni odmerek (5 mg na dan) ni rutinsko priporo en, vendar ga je treba upoštevati pri bolnikih, starih 65 let in ve, kadar to upravi ujejo klini ni dejavniki (glejte poglavje 4. 4).
Renal and/ or hepatic impairment A lower starting dose (5 mg) should be considered for such patients.
Okvarjeno ledvi no in/ ali jetrno delovanje Pri teh bolnikih je treba upoštevati nižji za etni odmerek (5 mg).
In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh Class A or B), the starting dose should be 5 mg and only increased with caution.
V primerih zmerno okvarjenega delovanja jeter (ciroza, Child- Pugh razreda A ali B) mora biti za etni odmerek 5 mg in se lahko zvišuje le previdno.
Gender The starting dose and dose range need not be routinely altered for female patients relative to male patients.
Spol Za etnega odmerka in razpona odmerkov za bolnice ni treba rutinsko spreminjati glede na bolnike.
Smokers The starting dose and dose range need not be routinely altered for non-smokers relative to smokers.
Kadilci Za etnega odmerka in razpona odmerkov za nekadilce ni treba rutinsko spreminjati glede na kadilce.
When more than one factor is present which might result in slower metabolism (female gender, geriatric age, non-smoking status), consideration should be given to decreasing the starting dose.
Ob navzo nosti ve kot enega dejavnika, ki bi lahko prispeval k po asnejši presnovi (ženski spol, starostnik, nekadilec), je treba pretehtati znižanje za etnega odmerka.
In cases where dose increments of 2.5 mg are considered necessary, ZYPREXA coated tablets should be used.
V primerih, kjer so nujna višanja odmerkov po 2, 5 mg, je treba uporabljati ZYPREXA obložene tablete.
During antipsychotic treatment, improvement in the patient's clinical condition may take several days to some weeks.
Med zdravljenjem z antipsihotiki se lahko bolnikovo klini no stanje izboljša v nekaj dneh do nekaj tednih.
3 Dementia-related psychosis and/ or behavioural disturbances Olanzapine is not approved for the treatment of dementia-related psychosis and/ or behavioural disturbances and is not recommended for use in this particular group of patients because of an increase in mortality and the risk of cerebrovascular accident.
Psihoza povezana z demenco in/ ali vedenjske motnje Olanzapin ni odobren za zdravljenje bolnikov s psihozo, povezano z demenco in/ ali vedenjskimi motnjami ter ni priporo ljiv za uporabo pri teh skupinah bolnikov zaradi pove ane umrljivosti in tveganja za cerebrovaskularne dogodke.
1.5%, respectively).
V klini nih preskušanjih, kontroliranih s placebom (ki so trajali 6- 12 tednov), pri starejših bolnikih s psihozo, povezano z demenco in/ ali vedenjskimi motnjami (povpre na starost 78 let), je bilo 2- kratno pove anje incidence smrti pri bolnikih, zdravljenih z olanzapinom, v primerjavi z bolniki, zdravljenimi s placebom (3, 5% v primerjavi z 1, 5%).
The higher incidence of death was not associated with olanzapine dose (mean daily dose 4.4 mg) or duration of treatment.
Ve ja incidenca smrtnosti ni bila povezana z odmerkom olanzapina (povpre ni dnevni odmerek 4, 4 mg) ali trajanjem zdravljenja.
Risk factors that may predispose this patient population to increased mortality include age > 65 years, dysphagia, sedation, malnutrition and dehydration, pulmonary conditions (e. g., pneumonia, with or without aspiration), or concomitant use of benzodiazepines.
Dejavniki tveganja, ki lahko povzro ijo ve jo dovzetnost te skupine bolnikov za pove ano umrljivost, vklju ujejo starost > 65 let, težave s požiranjem, sedacijo, nezadostno prehrano ali dehidracijo, obolenja plju (npr. plju nica, z aspiracijo ali brez nje), ali so asno uporabo benzodiazepinov.
However, the incidence of death was higher in olanzapine-treated than in placebo-treated patients independent of these risk factors.
Vendar je bila incidenca smrti, neodvisno od omenjenih dejavnikov tveganja, ve ja pri bolnikih zdravljenih z olanzapinom, kot pri bolnikih zdravljenih s placebom.
In the same clinical trials, cerebrovascular adverse events (CVAE e. g., stroke, transient ischemic attack), including fatalities, were reported.
V istih klini nih preskušanjih so poro ali o cerebrovaskularnih neželenih dogodkih (cerebrovascular adverse events - CVAE, npr. o možganski kapi, tranzitorni ishemi ni ataki), vklju no s smrtnimi izidi.
0.4%, respectively).
Pri bolnikih, zdravljenih z olanzapinom, je bila 3- krat ve ja pojavnost CVAE v primerjavi z bolniki, ki so prejemali placebo (1, 3% v primerjavi z 0, 4%).
All olanzapine- and placebo-treated patients who experienced a cerebrovascular event had pre-existing risk factors.
Vsi bolniki, ki so prejemali olanzapin ali placebo in so doživeli cerebrovaskularni dogodek, so imeli prej obstoje e dejavnike tveganja.
Age > 75 years and vascular/ mixed type dementia were identified as risk factors for CVAE in association with olanzapine treatment.
Starost > 75 let in vaskularna/ mešana demenca sta bili dolo eni kot dejavnika, ki prispevata k tveganju za CVAE v povezavi z zdravljenjem z olanzapinom.
The efficacy of olanzapine was not established in these trials.
V teh preskušanjih niso ugotavljali u inkovitosti olanzapina.
Parkinson's disease The use of olanzapine in the treatment of dopamine agonist associated psychosis in patients with Parkinson's disease is not recommended.
Parkinsonova bolezen Uporaba olanzapina pri zdravljenju psihoze, povezane z dopaminskimi agonisti, pri bolnikih s Parkinsonovo boleznijo ni priporo ena.
In clinical trials, worsening of Parkinsonian symptomatology and hallucinations were reported very commonly and more frequently than with placebo (see section 4.8), and olanzapine was not more effective than placebo in the treatment of psychotic symptoms.
V klini nih preskušanjih so o poslabšanju parkinsonske simptomatike in halucinacijah poro ali zelo pogosto in pogosteje kot pri placebu (glejte poglavje 4. 8), olanzapin pa ni bil bolj u inkovit kot placebo pri zdravljenju psihoti nih simptomov.
In these trials, patients were initially required to be stable on the lowest effective dose of anti- Parkinsonian medicinal products (dopamine agonist) and to remain on the same anti-Parkinsonian medicinal products and dosages throughout the study.
V teh preskušanjih je bilo potrebno, da se je zdravstveno stanje bolnikov najprej ustalilo ob prejemanju najnižjega u inkovitega odmerka antiparkinsonskih zdravil (dopaminskih agonistov) ter da so ves as študije prejemali ista antiparkinsonska zdravila v enakih odmerkih.
Olanzapine was started at 2.5 mg/ day and titrated to a maximum of 15 mg/ day based on investigator judgement.
Za etni odmerek olanzapina je bil 2, 5 mg na dan in nato postopoma zviševan do najvišjega odmerka 15 mg na dan na podlagi presoje preiskovalca.
Neuroleptic Malignant Syndrome (NMS) NMS is a potentially life-threatening condition associated with antipsychotic medicinal product.
Nevrolepti ni maligni sindrom (NMS) NMS je potencialno življenje ogrožajo e stanje, povezano z antipsihotiki.
Rare cases reported as NMS have also been received in association with olanzapine.
Poro ali so tudi o redkih primerih NMS v povezavi z olanzapinom.
Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia).
Klini ne manifestacije NMS so zvišana telesna temperatura, okorelost mišic, motnje zavesti in znaki avtonomne nestabilnosti (nepravilen sr ni utrip ali neurejen krvni tlak, tahikardija, prekomerno znojenje in motnje sr nega ritma).
If a patient develops signs and symptoms indicative of NMS, or presents with unexplained high fever without additional clinical manifestations of NMS, all antipsychotic medicines, including olanzapine must be discontinued.
Dodatni znaki lahko vklju ujejo zvišano kreatin- kinazo, mioglobinurijo (rabdomioliza) in akutno ledvi no odpoved. e bolnik razvije znake in simptome, ki kažejo na NMS, ali ima nerazložljivo visoko telesno temperaturo brez dodatnih klini nih manifestacij NMS, je treba prekiniti zdravljenje z vsemi antipsihotiki, vklju no z olanzapinom.
Hyperglycaemia and diabetes Hyperglycaemia and/ or development or exacerbation of diabetes occasionally associated with ketoacidosis or coma has been reported rarely, including some fatal cases (see section 4.8).
Hiperglikemija in diabetes Redko so poro ali o hiperglikemiji in/ ali razvoju ali poslabšanju sladkorne bolezni, ob asno povezanih s ketoacidozo ali komo, vklju ujo nekaj primerov s smrtnim izidom (glejte poglavje 4. 4).
In some cases, a prior increase in body weight has been reported which may be a predisposing factor.
Pri nekaterih primerih so poro ali o predhodnem pove anju telesne mase, kar bi lahko bil predisponirajo i dejavnik.
Appropriate clinical monitoring is advisable particularly in diabetic patients and in patients with risk factors for the development of diabetes mellitus for which regular glucose control is recommended.
4 sladkorne bolezni, za katero je priporo en reden nadzor glukoze, je priporo eno ustrezno klini no spremljanje.
Lipid alterations Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebo- controlled clinical trials (see section 4.8).
Spremembe lipidov V klini nih preskušanjih, kontroliranih s placebom, so pri bolnikih zdravljenih z olanzapinom opažali neželene spremembe lipidov (glejte poglavje 4. 8).
Lipid alterations should be managed as clinically appropriate, particularly in dyslipidemic patients and in patients with risk factors for the development of lipids disorders.
Na spremembe lipidov se je potrebno odzvati kot je klini no primerno, zlasti pri bolnikih z dislipidemijo in bolnikih z dejavniki tveganja za razvoj motenj lipidov.
4 Anticholinergic activity While olanzapine demonstrated anticholinergic activity in vitro, experience during the clinical trials revealed a low incidence of related events.
Antiholinergi no delovanje Medtem ko je olanzapin pokazal antiholinergi no delovanje v pogojih in vitro, so izkušnje klini nih preskušanj razkrile majhno incidenco s tem povezanih dogodkov.
However, as clinical experience with olanzapine in patients with concomitant illness is limited, caution is advised when prescribing for patients with prostatic hypertrophy, or paralytic ileus and related conditions.
Ker so klini ne izkušnje z olanzapinom pri bolnikih s so asnimi drugimi boleznimi omejene, se priporo a previdnost pri predpisovanju bolnikom s hipertrofijo prostate ali paraliti nim ileusom in povezanimi stanji.
Hepatic function Transient, asymptomatic elevations of hepatic transaminases, alanine transferase (ALT), aspartate transferase (AST) have been seen commonly, especially in early treatment.
Jetrno delovanje Pogosto so opažali prehodna, asimptomatska zvišanja jetrnih transaminaz, alaninske transferaze (ALT) in aspartatne transferaze (AST), posebno na za etku zdravljenja.
Caution should be exercised in patients with elevated ALT and/ or AST, in patients with signs and symptoms of hepatic impairment, in patients with pre-existing conditions associated with limited hepatic functional reserve, and in patients who are being treated with potentially hepatotoxic medicines.
Pri bolnikih s zvišano ALT in/ ali AST, bolnikih z znaki in simptomi okvarjenega delovanja jeter, bolnikih s prej obstoje imi stanji, povezanimi z omejeno jetrno funkcionalno rezervo, in pri bolnikih, ki se zdravijo s potencialno hepatotoksi nimi zdravili, je potrebna previdnost.
In cases where hepatitis (including hepatocellular, cholestatic or mixed liver injury) has been diagnosed, olanzapine treatment should be discontinued.
V primerih, kjer je ugotovljen hepatitis (vklju no s hepatocelularno, holestatsko ali mešano okvaro jeter), je treba zdravljenje z olanzapinom prekiniti.
Neutropenia Caution should be exercised in patients with low leukocyte and/ or neutrophil counts for any reason, in patients receiving medicines known to cause neutropenia, in patients with a history of drug-induced bone marrow depression/ toxicity, in patients with bone marrow depression caused by concomitant illness, radiation therapy or chemotherapy and in patients with hypereosinophilic conditions or with myeloproliferative disease.
To velja tudi za bolnike, pri katerih se je v preteklosti pojavilo z zdravili povzro eno zavrto delovanje kostnega mozga ali so prejemali zdravila, toksi na za kostni mozeg, pri bolnikih z zavrtim delovanjem kostnega mozga zaradi so asne bolezni, obsevanja ali kemoterapije ter pri bolnikih s hipereozinofilnimi stanji ali mieloproliferativno boleznijo.
Neutropenia has been reported commonly when olanzapine and valproate are used concomitantly (see section 4.8).
Ob so asni uporabi olanzapina in valproata so pogosto poro ali o nevtropeniji (glejte poglavje 4. 8).
Discontinuation of treatment Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported very rarely (< 0.01%) when olanzapine is stopped abruptly.
Prekinitev zdravljenja Zelo redko (< 0, 01%) so pri nenadni prekinitvi zdravljenja z olanzapinom poro ali o akutnih simptomih, kot so znojenje, nespe nost, tresenje, ob utek tesnobe, slabost ali bruhanje.
QT interval In clinical trials, clinically meaningful QTc prolongations (Fridericia QT correction [QTcF] 500 milliseconds [msec] at any time post baseline in patients with baseline QTcF < 500 msec) were uncommon (0.1% to 1%) in patients treated with olanzapine, with no significant differences in associated cardiac events compared to placebo.
QT interval V klini nih preskušanjih so bila klini no pomembna podaljšanja QTc (QT korekcija Fridericia [QTcF] 500 milisekund [msek] kadarkoli nad osnovno vrednostjo pri bolnikih z osnovno vrednostjo QTcF < 500 msek) pri bolnikih, zdravljenih z olanzapinom, redka (od 0, 1% do 1%), brez pomembnih razlik v spremljajo ih sr nih dogodkih v primerjavi z bolniki, zdravljenimi s placebom.
However, as with other antipsychotics, caution should be exercised when olanzapine is prescribed with medicines known to increase QTc interval, especially in the elderly, in patients with congenital long QT syndrome, congestive heart failure, heart hypertrophy, hypokalaemia or hypomagnesaemia.
Vendar pa je kot pri drugih antipsihotikih potrebna previdnost, kadar predpisujemo olanzapin skupaj z zdravili, za katera je znano, da podaljšujejo QTc interval, posebno pri starejših, pri bolnikih s prirojenim sindromom dolgega QT intervala, kongestivnim popuš anjem srca, hipertrofijo srca, hipokaliemijo ali hipomagnezemijo.
Thromboembolism Temporal association of olanzapine treatment and venous thromboembolism has very rarely (< 0.01%) been reported.
Trombembolija Zelo redko (< 0, 01%) so poro ali o ob asnih povezavah med zdravljenjem z olanzapinom in vensko tromboembolijo.
A causal relationship between the occurrence of venous thromboembolism and treatment with olanzapine has not been established.
Vzro ne povezave med pojavnostjo venske tromboembolije in zdravljenjem z olanzapinom niso ugotovili.
General CNS activity Given the primary CNS effects of olanzapine, caution should be used when it is taken in combination with other centrally acting medicines and alcohol.
5 Splošno delovanje na osrednje živ evje Glede na primarne u inke olanzapina na osrednje živ evje je potrebna previdnost, kadar se ga jemlje v kombinaciji z drugimi osrednje delujo imi zdravili in alkoholom.
As it exhibits in vitro dopamine antagonism, olanzapine may antagonize the effects of direct and indirect dopamine agonists.
Ker v pogojih in vitro kaže dopaminski antagonizem, olanzapin lahko nasprotuje u inkom direktnih in indirektnih dopaminskih agonistov.
Seizures Olanzapine should be used cautiously in patients who have a history of seizures or are subject to factors which may lower the seizure threshold.
Epilepti ni napadi Olanzapin je treba uporabljati previdno pri bolnikih, ki so imeli v preteklosti epilepti ne napade ali so podvrženi dejavnikom, ki bi lahko znižali prag za epilepti ne napade.
Seizures have been reported to occur rarely in patients when treated with olanzapine.
Pri bolnikih, ki so se zdravili z olanzapinom, so o epilepti nih napadih poro ali redko.
In most of these cases, a history of seizures or risk factors for seizures were reported.
Pri ve ini teh primerov so o teh napadih poro ali že v preteklosti ali so bili navzo i dejavniki tveganja za epilepti ni napad.
5 Tardive Dyskinesia In comparator studies of one year or less duration, olanzapine was associated with a statistically significant lower incidence of treatment emergent dyskinesia.
Tardivne diskinezije V primerjalnih študijah, ki so trajale eno leto ali manj, so olanzapin povezovali s statisti no zna ilno manjšo incidenco diskinezij, ki se pojavijo ob zdravljenju.
However the risk of tardive dyskinesia increases with long term exposure, and therefore if signs or symptoms of tardive dyskinesia appear in a patient on olanzapine, a dose reduction or discontinuation should be considered.
Vendar pa tveganje za tardivne diskinezije naraš a s trajanjem zdravljenja in je zato ob pojavu znakov ali simptomov tardivnih diskinezij pri bolniku, ki prejema olanzapin, treba razmisliti o znižanju odmerka ali ukinitvi zdravila.
These symptoms can temporally deteriorate or even arise after discontinuation of treatment.
Ti simptomi se lahko s asom poslabšajo ali se pojavijo celo po ukinitvi zdravljenja.
Postural hypotension Postural hypotension was infrequently observed in the elderly in olanzapine clinical trials.
Posturalna hipotenzija V klini nih preskušanjih olanzapina so pri starejših redko poro ali o posturalni hipotenziji.
As with other antipsychotics, it is recommended that blood pressure is measured periodically in patients over 65 years.
Kot pri drugih antipsihotikih je priporo eno redno merjenje krvnega tlaka pri bolnikih, starejših od 65 let.
Studies in patients aged 13-17 years showed various adverse reactions, including weight gain, changes in metabolic parameters and increases in prolactin levels.
Študije pri bolnikih, starih 13- 17 let kažejo na razli ne neželene u inke, vklju no s pove anjem telesne mase, spremembami v kazalcih presnove in zvišanjih ravni prolaktina.
Long-term outcomes associated with these events have not been studied and remain unknown (see sections 4.8 and 5.1).
Dolgoro nih posledic, povezanih s temi u inki niso preu evali in ostajajo neznani (glejte poglavji 4. 8 in 5. 1).
Phenylalanine ZYPREXA VELOTAB orodispersible tablet contains aspartame, which is a source of phenylalanine.
Fenilalanin ZYPREXA VELOTAB orodisperzibilna tableta vsebuje aspartam, ki je vir fenilalanina.
These preservatives are known to cause urticaria.
Za ta dva konzervansa je znano, da povzro ata koprivnico.
Generally, delayed type reactions such as contact dermatitis may occur, but rarely immediate reactions with bronchospasm may occur.
Na splošno lahko pride do reakcij pozne preob utljivosti, kot je kontaktni dermatitis, le redko pa se pojavijo reakcije takojšnje preob utljivosti z bronhospazmom.
Potential interactions affecting olanzapine Since olanzapine is metabolised by CYP1A2, substances that can specifically induce or inhibit this isoenzyme may affect the pharmacokinetics of olanzapine.
Možna medsebojna delovanja, ki vplivajo na olanzapin Ker se olanzapin presnavlja s CYP1A2, utegnejo snovi, ki lahko specifi no inducirajo ali inhibirajo ta izoencim, vplivati na farmakokinetiko olanzapina.
Induction of CYP1A2 The metabolism of olanzapine may be induced by smoking and carbamazepine, which may lead to reduced olanzapine concentrations.
Indukcija CYP1A2 Presnovo olanzapina lahko pospešita kajenje in karbamazepin, kar lahko povzro i znižane koncentracije olanzapina.
Only slight to moderate increase in olanzapine clearance has been observed.
Opažali so le blago do zmerno pove anje o istka olanzapina.
The clinical consequences are likely to be limited, but clinical monitoring is recommended and an increase of olanzapine dose may be considered if necessary (see section 4.2).
Klini ne posledice so verjetno omejene, vendar je priporo eno spremljanje klini nega stanja in zvišanje odmerka olanzapina, e je potrebno (glejte poglavje 4. 2).
Inhibition of CYP1A2 Fluvoxamine, a specific CYP1A2 inhibitor, has been shown to significantly inhibit the metabolism of olanzapine.
6 Zaviranje CYP1A2 Fluvoksamin, specifi ni zaviralec CYP1A2, je pokazal pomembno zaviranje presnove olanzapina.
The mean increase in olanzapine AUC was 52% and 108% respectively.
Srednje pove anje AUC olanzapina je bilo 52% oziroma 108%.
A lower starting dose of olanzapine should be considered in patients who are using fluvoxamine or any other CYP1A2 inhibitors, such as ciprofloxacin.
Pri bolnikih, ki prejemajo fluvoksamin ali kake druge zaviralce CYP1A2, kot je ciprofloksacin, je treba pretehtati nižji za etni odmerek olanzapina.
A decrease in the dose of olanzapine should be considered if treatment with an inhibitor of CYP1A2 is initiated.
Upoštevati je treba znižanje odmerka olanzapina, e se uvede zdravljenje z zaviralcem CYP1A2.
6 Fluoxetine (a CYP2D6 inhibitor), single doses of antacid (aluminium, magnesium) or cimetidine have not been found to significantly affect the pharmacokinetics of olanzapine.
Za fluoksetin (zaviralec CYP2D6), posamezne odmerke antacida (aluminij, magnezij) ali cimetidina niso ugotovili, da bi zna ilno vplivali na farmakokinetiko olanzapina.
Potential for olanzapine to affect other medicinal products Olanzapine may antagonise the effects of direct and indirect dopamine agonists.
Zmožnost vplivanja olanzapina na druga zdravila Olanzapin lahko nasprotuje u inkom direktnih in indirektnih dopaminskih agonistov.
Thus no particular interaction is expected as verified through in vivo studies where no inhibition of metabolism of the following active substances was found: tricyclic antidepressant (representing mostly CYP2D6 pathway), warfarin (CYP2C9), theophylline (CYP1A2) or diazepam (CYP3A4 and 2C19).
Zato ni pri akovati kakega posebnega medsebojnega delovanja, kar je bilo potrjeno s študijami in vivo, kjer niso opazili nobenega zaviranja presnove naslednjih u inkovin: tricikli nih antidepresivov (ki predstavljajo predvsem pot CYP2D6), varfarina (CYP2C9), teofilina (CYP1A2) ali diazepama (CYP3A4 in 2C19).
Olanzapine showed no interaction when co-administered with lithium or biperiden.
Olanzapin ni kazal interakcij ob so asnem dajanju z litijem ali biperidenom.